Methamphetamine Use: A Narrative Review of Adverse Effects and Related Toxicities

Overview

Journal Health Psychol Res

Date 2022 Sep 19

PMID 36118981

Authors

Amber N Edinoff

Sarah E Kaufman

Keionne M Green

Daniel A Provenzano

Jesse Lawson

Elyse M Cornett

Kevin S Murnane

Adam M Kaye

Alan D Kaye

Affiliations

Soon will be listed here.

Abstract

Methamphetamine has been labeled "America's most dangerous drug" and has received significant public health attention. Stimulant addiction and tolerance are heavily documented in the literature; increasingly larger doses maintain euphoria in short time periods to withstand stimulant tolerance. Stimulant deaths are high in the United States and abroad. Between 2013 and 2019, deaths related to methamphetamine use quadrupled from 3,616 to 16,127. Methamphetamine use increased four-fold from 2015 to 2016. Due to this increase in methamphetamine use and its associated medical complications, the mortality rate associated with methamphetamine use has doubled over the past ten years. Cardiopulmonary symptoms include chest pain, palpitations, and shortness of breath. Methamphetamine-related myocardial infarction can also occur. Central nervous system symptoms include agitation, anxiety, delusions, hallucinations, and seizures. Methamphetamine-induced psychosis may unmask underlying psychiatric disorders. It can also cause cerebral vasculitis, which elicits cortical blindness and ischemic strokes. Methamphetamine-induced neurotoxicity in serotonergic systems is more diffuse, involving the striatum, hippocampus, septum, amygdala, and hypothalamus leading to mood changes, psychosis, and memory impairment. This narrative review will aim to highlight the adverse effects as well as the toxicity that can occur with methamphetamine use.

Citing Articles

Practices and attitudes of adult psychiatrists regarding methamphetamine-associated psychotic disorder: an internet based survey conducted in Turkey.

Orum M, Kapici Y, Sonmez D, Tanrikulu A, Gumusay M, Kochan O BMC Health Serv Res. 2025; 25(1):20.

PMID: 39754117 PMC: 11699667. DOI: 10.1186/s12913-024-12134-1.

Cannabidiol Plays a Modulatory Function on the Methamphetamine-Induced Reward Through Hippocampal D2-Like Dopamine Receptors.

Mohammadi M, Omidiani S, Azizbeigi R, Haghparast A Neurochem Res. 2024; 50(1):6.

PMID: 39540967 DOI: 10.1007/s11064-024-04256-z.

Molecular Mechanisms of Methamphetamine-Induced Addiction via TAAR1 Activation.

Lin Y, Wang J, Shi F, Yang L, Wu S, Qiao A J Med Chem. 2024; 67(20):18593-18605.

PMID: 39358311 PMC: 11513891. DOI: 10.1021/acs.jmedchem.4c01961.

Methamphetamine dependence in Australia-why is 'ice' (crystal meth) so addictive?.

Scott R Psychiatr Psychol Law. 2024; 31(4):671-704.

PMID: 39118784 PMC: 11305059. DOI: 10.1080/13218719.2023.2206870.

Urinary Retention Following Methamphetamine and Cannabis Abuse in a 33-Year-Old Male.

Kaur N, Haleem M, Espiridion E Cureus. 2024; 16(3):e57033.

PMID: 38681277 PMC: 11047220. DOI: 10.7759/cureus.57033.

References

Matsumoto R, Seminerio M, Turner R, Robson M, Nguyen L, Miller D . Methamphetamine-induced toxicity: an updated review on issues related to hyperthermia. Pharmacol Ther. 2014; 144(1):28-40. PMC: 4700537. DOI: 10.1016/j.pharmthera.2014.05.001. View

Batra V, Murnane K, Knox B, Edinoff A, Ghaffar Y, Nussdorf L . Early onset cardiovascular disease related to methamphetamine use is most striking in individuals under 30: A retrospective chart review. Addict Behav Rep. 2022; 15:100435. PMC: 9127267. DOI: 10.1016/j.abrep.2022.100435. View

Darke S, Kaye S, McKetin R, Duflou J . Major physical and psychological harms of methamphetamine use. Drug Alcohol Rev. 2008; 27(3):253-62. DOI: 10.1080/09595230801923702. View

Vocci F, Appel N . Approaches to the development of medications for the treatment of methamphetamine dependence. Addiction. 2007; 102 Suppl 1:96-106. DOI: 10.1111/j.1360-0443.2007.01772.x. View

Shin E, Dang D, Tran T, Tran H, Jeong J, Nah S . Current understanding of methamphetamine-associated dopaminergic neurodegeneration and psychotoxic behaviors. Arch Pharm Res. 2017; 40(4):403-428. DOI: 10.1007/s12272-017-0897-y. View

Gorman M, Orme K, Nguyen N, Kent 3rd E, Caughey A . Outcomes in pregnancies complicated by methamphetamine use. Am J Obstet Gynecol. 2014; 211(4):429.e1-7. DOI: 10.1016/j.ajog.2014.06.005. View

Maheshwari M, Athiraman H . "Speedballing" to Severe Rhabdomyolysis and Hemodialysis in a 27-Year-Old Male. Cureus. 2022; 13(12):e20667. PMC: 8712215. DOI: 10.7759/cureus.20667. View

Kipke M, OConnor S, Palmer R, MacKenzie R . Street youth in Los Angeles. Profile of a group at high risk for human immunodeficiency virus infection. Arch Pediatr Adolesc Med. 1995; 149(5):513-9. DOI: 10.1001/archpedi.1995.02170180043006. View

Tobias M, ONeill J, Hudkins M, Bartzokis G, Dean A, London E . White-matter abnormalities in brain during early abstinence from methamphetamine abuse. Psychopharmacology (Berl). 2010; 209(1):13-24. PMC: 2819660. DOI: 10.1007/s00213-009-1761-7. View

10.

Roohbakhsh A, Shirani K, Karimi G . Methamphetamine-induced toxicity: The role of autophagy?. Chem Biol Interact. 2016; 260:163-167. DOI: 10.1016/j.cbi.2016.10.012. View

11.

Yimsaard P, Maes M, Verachai V, Kalayasiri R . Pattern of Methamphetamine Use and the Time Lag to Methamphetamine Dependence. J Addict Med. 2017; 12(2):92-98. PMC: 5847435. DOI: 10.1097/ADM.0000000000000371. View

12.

Gonzales R, Mooney L, Rawson R . The methamphetamine problem in the United States. Annu Rev Public Health. 2010; 31:385-98. PMC: 4440680. DOI: 10.1146/annurev.publhealth.012809.103600. View

13.

Morales A, Lee B, Hellemann G, ONeill J, London E . Gray-matter volume in methamphetamine dependence: cigarette smoking and changes with abstinence from methamphetamine. Drug Alcohol Depend. 2012; 125(3):230-8. PMC: 3427723. DOI: 10.1016/j.drugalcdep.2012.02.017. View

14.

Zweben J, Cohen J, Christian D, Galloway G, Salinardi M, Parent D . Psychiatric symptoms in methamphetamine users. Am J Addict. 2004; 13(2):181-90. DOI: 10.1080/10550490490436055. View

15.

Glasner-Edwards S, Mooney L, Marinelli-Casey P, Hillhouse M, Ang A, Rawson R . Clinical course and outcomes of methamphetamine-dependent adults with psychosis. J Subst Abuse Treat. 2008; 35(4):445-50. DOI: 10.1016/j.jsat.2007.12.004. View

16.

Smid M, Metz T, Gordon A . Stimulant Use in Pregnancy: An Under-recognized Epidemic Among Pregnant Women. Clin Obstet Gynecol. 2019; 62(1):168-184. PMC: 6438363. DOI: 10.1097/GRF.0000000000000418. View

17.

Schuckit M . Comorbidity between substance use disorders and psychiatric conditions. Addiction. 2006; 101 Suppl 1:76-88. DOI: 10.1111/j.1360-0443.2006.01592.x. View

18.

Murnane K, Perrine S, Finton B, Galloway M, Howell L, Fantegrossi W . Effects of exposure to amphetamine derivatives on passive avoidance performance and the central levels of monoamines and their metabolites in mice: correlations between behavior and neurochemistry. Psychopharmacology (Berl). 2011; 220(3):495-508. PMC: 3289749. DOI: 10.1007/s00213-011-2504-0. View

19.

Paulus M, Stewart J . Neurobiology, Clinical Presentation, and Treatment of Methamphetamine Use Disorder: A Review. JAMA Psychiatry. 2020; 77(9):959-966. PMC: 8098650. DOI: 10.1001/jamapsychiatry.2020.0246. View

20.

Pillai S, Cesarz B, Boulware C, Khan A . Hypotension, Severe Hyperthermia (42°C), Rhabdomyolysis, and Disseminated Intravascular Coagulation Induced by Lethal Dose of Methamphetamine. Cureus. 2019; 11(7):e5245. PMC: 6759040. DOI: 10.7759/cureus.5245. View